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TO THE EDITOR
Cellular senescence is an irreversible
withdrawal from the cell cycle without
cell death, and may represent a barrier
to malignancy. Replicative senescence
results from critical telomere shorten-
ing, which may be overcome in tumors
by expression of the hTERT (human
telomerase reverse transcriptase) telo-
merase (Bodnar et al., 1998). Sene-
scence may also occur independent of
telomere shortening, through expres-
sion of single oncogenes (such as
members of the Ras pathway) in other-
wise genetically intact cells including
melanocytes (Serrano et al., 1997;
Pollock et al., 2003). These findings
suggest that oncogene-induced senes-
cence represents a barrier to transfor-
mation from nevus to melanoma (Mooi
and Peeper, 2006). In support of this
notion, two groups (Michaloglou et al.,
2005; Gray-Schopfer et al., 2006)
recently reported expression of sene-
scence-associated beta-galactosidase
(SA-b-gal) in 100% of nevi examined.
We investigated expression of SA-
b-gal in a panel of adult nevi, including
congenital, common, and dysplastic
histologic subtypes. First, we validated
the routinely used SA-b-gal (pH 6)
staining protocol (Dimri et al., 1995)
using both early and late passage
normal human foreskin melanocytes,
which were prepared and propagated
as described previously (Bowen et al.,
2003). As expected, b-gal activity at pH
6 was detected in late (Figure 1c) but
not early (Figure 1a) passage cells.
Interestingly, b-gal activity was not only
detectable in late passage cells demons-
trating (senescence-like) spread-out
morphology but also in those bearing
the spindled dendritic morphology of
earlier passage cells (Figure 1c). As a
control, staining was also performed at
pH 4, which optimally detects lyso-
somal b-gal (Morreau et al., 1989), and
both early and late passage cells de-
monstrated robust pH 4 b-gal staining
(Figure 1b and d). We then applied this
staining technique to a panel of 17
freshly frozen adult nevi, collected with
patient consent in accordance with the
Declaration of Helsinki Principles and
as approved by the Institutional Review
Board at the University of Utah (no.
19304). Specimens were trisected at the
time of biopsy, with the central section
placed in formalin and sent for histo-
pathologic analysis by a dermatopathol-
ogist (S.R.F.). The flanking pieces were
oriented and embedded in OCT com-
pound (tissue-tek), and stored at 801C.
After confirming the central section was
adequate for diagnostic purposes, we
proceeded with b-gal staining at pH 4,
5, and 6 on 8-mm frozen sections.
The data are summarized in Table 1.
Although every specimen evaluated
showed varying degrees of positivity at
the optimal pH 4 (Figure 1f), none of
the specimens showed staining at pH 6
(i.e. SA-b-gal) (Figure 1e and Table 1).
Staining at pH 5 was present only in
specimens that showed strong staining
at pH 4, and when present, was
generally intermediate to staining seen
at pH 4 and 6 (Table 1). Given the
somewhat surprising absence of b-gal
staining at pH 6 in all 17 nevi examined
(including several congenital and in-
tradermal subtypes), we performed an
additional procedural control by stain-
ing late and early passage melanocytes
in frozen sections which had been
prepared similarly (as the nevi) in
OCT. Thus, the cells were treated
exactly as the tissue was handled: cells
were pelleted, resuspended in OCT,
frozen, cryostat-sectioned, and then
fixed and stained precisely in parallel
with the nevus specimens. These cells
showed the same staining pattern (Fig-
ure 1g–j) as seen when stained in
culture (Figure 1a–d), thus confirming
that the absence of pH 6 b-gal staining
in nevi was not due to an artifact of
specimen processing.
Our demonstration of uniformly ne-
gative pH 6 b-gal staining in a panel of
nevi stands in stark contrast with recent
reports of positive staining in 23/23
congenital nevi from patients less than
1 year of age (Michaloglou et al., 2005)
and 7/7 congenital nevi greater than
1 cm (donor age unspecified) (Gray-
Schopfer et al., 2006). We only studied
nevi from adults, and did not have
access to congenital nevi from infants.
Although it is possible that only con-
genital nevi from the very young subject
express this marker and it is gradually
lost over time, it is somewhat counter-
intuitive that such nevi are senescent, as
they grow during this period and carry
some risk of transformation. We also
considered the possibility that previous
data may have been generated under
conditions of incompletely controlled
pH resulting in detection of b-gal activity
at lower pHs than intended. In our
experiments, the pH of the staining
solution was confirmed after overnight
incubation at 371C in a non-CO2
enriched environment.
Campisi and co-workers (Dimri
et al., 1995) first proposed SA-b-gal as
a marker for senescence based on
selective staining (at pH 6) of late but
not early passage epidermal cells, and
the skin of older individuals (469
years). The authors noted, however,
that early passage adult melanocytes
growing in culture (490%) expressed
b-gal activity at pH 6 (Dimri et al.,
1995). It is also curious that in aged
skin, the reported pH 6 b-gal staining
appears localized to a narrow band
within the epidermis likely to contain
mitotically active cells and was nega-
tive in the upper layers likely to contain
terminally differentiated cells (Dimri
et al., 1995). Recent studies have in
fact called into question the validity of
pH 6 b-gal activity as a marker forAbbreviations: PBS, phosphate-buffered saline; SA-b-gal, senescence-associated beta-galactosidase
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senescence, and suggest that it more
likely represents a nonspecific marker
of lysosomes. Pharmacologic alkalini-
zation of the lysosomal compartment
eliminates b-gal activity in both early
and late passage human umbilical vein
endothelial cells, and lysosomal con-
tent increased with replicative age in
parallel with increasing b-gal activity
(Kurz et al., 2000), suggesting that
acquisition of pH 6 b-gal activity
reflects expansion of the lysosomal
compartment known to occur through
serial rounds of cell division (Robbins
et al., 1970; Brunk et al., 1973). More-
over, human fibroblasts either deficient
in the single human b-gal-encoding
gene GLB1 or treated with GLB1-
interfering RNA underwent replicative
senescence (Lee et al., 2006). Thus, pH
6 b-gal is neither necessary nor suffi-
cient for the induction of senescence,
and the intermediate level of b-gal
staining we observed at pH 5 supports
the notion that staining at pH 6,
when present, detects an increase of
the same enzyme activity seen opti-
mally at pH 4.
Our data suggest that most benign
human nevi are unlikely to show
detectable pH 6 b-gal activity, and thus
it seems premature to conclude that
nevi are senescent due to oncogene
activation. After all, nevomelanocytes
in vivo are not synonymous with
melanocytes in vitro. Furthermore, gi-
ven the fact that pH 6 b-gal staining
simply detects the lysosomal expansion
associated with cellular passages and is
not required for senescence develop-
ment in vitro, we suggest the need for
more specific and biologically relevant
markers of senescence in vivo. Only
then we can better interrogate the
attractive hypothesis that melanoma
may arise, in part, from either an escape
from or failure to develop a senescent
phenotype in nevomelanocytes.
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Figure 1. Detection of b-gal activity in vitro and in vivo. Melanocytes from (a, b) passage 2 (early) and (c, d) passage 12 (late) cultures were stained as
described (Dimri et al., 1995). Briefly, cells were washed with phosphate-buffered saline (PBS) and fixed with 1% paraformaldehyde for 3 minutes at room
temperature, then washed three times with PBS for 5 minutes each at room temperature. Staining was performed overnight in a non-CO2 enriched incubator at
371C using a solution (pH 4 or pH 6 as indicated) containing 40 mM sodium phosphate (dibasic), 40 mM citric acid, 150 mM NaCl, 2 mM MgCl2, 5 mM potassium
ferrocyanide, 5 mM potassium ferricyanide, 1 mg/ml X-gal (5-bromo-4-chloro-3-indolyl-b-D-galactoside, Pierce Chemical Co., Rockford, IL). Cyanide salts and
X-gal were added from freshly made 100 stocks in PBS and dimethylformamide, respectively. Cells were then washed three times with PBS for 5 minutes each
at room temperature, before microscopic examination and photography (original magnification  200). (e, f) Nevus no. 5 (Table 1). Frozen sections were fixed
and stained as above (with additional staining at pH 5), followed by counterstaining with eosin, alcohol dehydration, and mounting before microscopic
examination and photography (original magnification 400). (g, h) Passage 3 melanocytes and (i, j) passage 15 melanocytes were trypsinized, washed with
PBS, and resuspended in OCT before frozen sectioning. Sections were then fixed and stained in parallel with nevi, as above (original magnification  400).
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Table 1. Descriptions and b-gal staining patterns of nevi examined
Nos. Age (years) Sex Site Diagnosis b-Gal pH 4 b-Gal pH 5 b-Gal pH 6
1 48 F Chest Nevus, congenital growth pattern 1+ ND Neg.
2 48 M Arm Nevus, congenital growth pattern 2+ 1+ Neg.
3 29 M Back Dysplastic nevus 1+ 1+ Neg.
4 27 F Back Dysplastic nevus 1+ Neg. Neg.
5 48 F Groin Compound nevus 3+ 1+ Neg.
6 36 M Back Dysplastic nevus 2+ Neg. Neg.
7 61 F Lower leg Nevus, congenital growth pattern 3+ 2+ Neg.
8 23 M Back Dysplastic nevus 2+ 1+ Neg.
9 33 F Back Nevus, congenital growth pattern 3+ 2+ Neg.
10 23 F Groin Compound nevus 1+ Neg. Neg.
11 44 F Hand Nevus, congenital growth pattern 3+ 3+ Neg.
12 73 F Chin Intradermal nevus 1+ 1+ Neg.
13 28 M Back Nevus, congenital growth pattern 2+ 2+ Neg.
14 34 F Upper arm Blue nevus Focal/1+ Neg. Neg.
15 30 F Shoulder Dysplastic nevus 1+ Neg. Neg.
16 56 F Back Intradermal nevus 1+ 1+ Neg.
17 57 M Back Intradermal nevus 2+ 2+ Neg.
F, female; M, male.
Scoring: Neg., negative staining; 1+, o25% cells positive; 2+, 25–75% cells positive; 3+, 75–100% cells positive; ND, not done.
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